Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Breast 2

Conditions

Prostatic Neoplasms 2Hypogonadism 2Osteoporosis 1

Interventions

Docetaxel 77Radiotherapy 73Prednisone 66Leuprolide 51Goserelin 49Gemcitabine 49Cisplatin 48bicalutamide 46enzalutamide 43Androgen Antagonists 36pembrolizumab 32Abiraterone Acetate 31Mitomycin 29acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28Magnetic Resonance Spectroscopy 28Carboplatin 27Flutamide 25Nivolumab 24Triptorelin Pamoate 23Sunitinib 23apalutamide 22Radiation 22Doxorubicin 20darolutamide 19abiraterone 18Gonadotropin-Releasing Hormone 18cabozantinib 17atezolizumab 16Specimen Handling 16Radiosurgery 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Alendronate × Genitourinary × Clear all
NCT00177619 2014-02-11

Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study)

University of Pittsburgh

Phase 3 Completed
120 enrolled
Genitourinary

Hypogonadism, Prostatic Neoplasms

NCT00048841 2010-03-02

Prevention of Osteoporosis in Men With Prostate Cancer

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase 3 Completed
112 enrolled
Genitourinary

Hypogonadism, Osteoporosis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡